Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States

Published:2019-09-13 Issue:1 Volume:36 Page:23-32
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Sullivan Patrick W.¹,Li Qianyi²,Bilir S. Pinar²,Dang Joseph³,Kavati Abhishek⁴,Yang Ming³,Rajput Yamina³

Affiliation:

1. Regis University School of Pharmacy, Denver, CO, USA;

2. IQVIA, San Francisco, CA, USA;

3. Genentech, Inc., South San Francisco, CA, USA;

4. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1660539

Reference58 articles.

1. null

2. Centers for Disease Control and Prevention. Deaths: final data for 2015. Supplemental Tables. Tables I-24, I-25; National Vital Statistics Reports; 2017;66(6). Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06_tables.pdf.

3. Centers for Disease Control and Prevention. Most recent asthma data; 2018. Available from: https://www.cdc.gov/asthma/most_recent_data.htm.

4. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma; 2007. Available from: https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln_1.pdf.

5. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy;The Journal of Allergy and Clinical Immunology: In Practice;2024-09

2. Evaluating the relationship between health-related social needs, patient demographics, and access to biologics in patients with moderate-to-severe asthma in Bronx, NY;Journal of Asthma;2024-06-14

3. Cost effectiveness of omalizumab for severe asthma in Colombia;Journal of Asthma;2023-10-10

4. Cost-effectiveness of tezepelumab in Canada for severe asthma;Journal of Medical Economics;2023-07-17

5. Economic evaluation of biological treatments in patients with severe asthma: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-09